Meeting highlights from the Pharmacovigilance Risk Assessment Committee.
European Medicines Agency’s safety committee (PRAC) has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 Receptor Agonists (GLP-1) – exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide – and cancer of the thyroid (a small…